104 related articles for article (PubMed ID: 9180387)
1. Activity of TER286 against human tumor colony-forming units.
Izbicka E; Lawrence R; Cerna C; Von Hoff DD; Sanderson PE
Anticancer Drugs; 1997 Apr; 8(4):345-8. PubMed ID: 9180387
[TBL] [Abstract][Full Text] [Related]
2. Tumor efficacy and bone marrow-sparing properties of TER286, a cytotoxin activated by glutathione S-transferase.
Morgan AS; Sanderson PE; Borch RF; Tew KD; Niitsu Y; Takayama T; Von Hoff DD; Izbicka E; Mangold G; Paul C; Broberg U; Mannervik B; Henner WD; Kauvar LM
Cancer Res; 1998 Jun; 58(12):2568-75. PubMed ID: 9635580
[TBL] [Abstract][Full Text] [Related]
3. Cellular response to a glutathione S-transferase P1-1 activated prodrug.
Rosario LA; O'Brien ML; Henderson CJ; Wolf CR; Tew KD
Mol Pharmacol; 2000 Jul; 58(1):167-74. PubMed ID: 10860939
[TBL] [Abstract][Full Text] [Related]
4. Activity of temozolomide against human tumor colony-forming units.
Raymond E; Izbicka E; Soda H; Gerson SL; Dugan M; Von Hoff DD
Clin Cancer Res; 1997 Oct; 3(10):1769-74. PubMed ID: 9815562
[TBL] [Abstract][Full Text] [Related]
5. Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Petit T; Izbicka E; Lawrence RA; Bishop WR; Weitman S; Von Hoff DD
Ann Oncol; 1999 Apr; 10(4):449-53. PubMed ID: 10370788
[TBL] [Abstract][Full Text] [Related]
6. Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units.
Siu LL; Von Hoff DD; Rephaeli A; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Eckhardt SG
Invest New Drugs; 1998; 16(2):113-9. PubMed ID: 9848574
[TBL] [Abstract][Full Text] [Related]
7. FK317, a novel substituted dihydrobenzoxazine, exhibits potent antitumor activity against human tumor xenografts in nude mice.
Naoe Y; Inami M; Matsumoto S; Takagaki S; Fujiwara T; Yamazaki S; Kawamura I; Nishigaki F; Tsujimoto S; Manda T; Shimomura K
Jpn J Cancer Res; 1998 Dec; 89(12):1306-17. PubMed ID: 10081492
[TBL] [Abstract][Full Text] [Related]
8. Activity of DMP 840, a new bis-naphthalimide, on primary human tumor colony-forming units.
Cobb PW; Degen DR; Clark GM; Chen SF; Kuhn JG; Gross JL; Kirshenbaum MR; Sun JH; Burris HA; Von Hoff DD
J Natl Cancer Inst; 1994 Oct; 86(19):1462-5. PubMed ID: 8089865
[TBL] [Abstract][Full Text] [Related]
9. Activity of oxaliplatin against human tumor colony-forming units.
Raymond E; Lawrence R; Izbicka E; Faivre S; Von Hoff DD
Clin Cancer Res; 1998 Apr; 4(4):1021-9. PubMed ID: 9563898
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy testing of human breast cancers in the soft agar clonogenic assay.
Osborne CK; Von Hoff DD; Mullins K
Breast Cancer Res Treat; 1985; 6(3):229-35. PubMed ID: 2936413
[TBL] [Abstract][Full Text] [Related]
11. A study of ethacrynic acid as a potential modifier of melphalan and cisplatin sensitivity in human lung cancer parental and drug-resistant cell lines.
Rhodes T; Twentyman PR
Br J Cancer; 1992 May; 65(5):684-90. PubMed ID: 1316774
[TBL] [Abstract][Full Text] [Related]
12. Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.
Raymond E; Hanauske A; Faivre S; Izbicka E; Clark G; Rowinsky EK; Von Hoff DD
Anticancer Drugs; 1997 Apr; 8(4):379-85. PubMed ID: 9180392
[TBL] [Abstract][Full Text] [Related]
13. Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.
Shimada Y; Rothenberg M; Hilsenbeck SG; Burris HA; Degen D; Von Hoff DD
Anticancer Drugs; 1994 Apr; 5(2):202-6. PubMed ID: 8049503
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity of drug resistance in human breast and ovarian cancers.
Kern DH
Cancer J Sci Am; 1998; 4(1):41-5. PubMed ID: 9467045
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of in vivo antitumor activity of classical anticancer agents by combination with the new, glutathione-interacting DNA minor groove-binder, brostallicin.
Sabatino MA; Colombo T; Geroni C; Marchini S; Broggini M
Clin Cancer Res; 2003 Nov; 9(14):5402-8. PubMed ID: 14614026
[TBL] [Abstract][Full Text] [Related]
16. Activity of the morpholino anthracycline 3'-deamino-3'-morpholino-13-deoxo-10-hydroxycarminomycin (MX2) against human tumor colony-forming units in vitro.
Ebrahim el-Zayat AA; Izquierdo MA; Clark GM; Von Hoff DD
Invest New Drugs; 1995; 13(2):125-131. PubMed ID: 8617574
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of the cyclopropylpyrroloindole compounds adozelesin, bizelesin and carzelesin in a human tumor colony-forming assay.
Hidalgo M; Izbicka E; Cerna C; Gomez L; Rowinsky EK; Weitman SD; Von Hoff DD
Anticancer Drugs; 1999 Mar; 10(3):295-302. PubMed ID: 10327036
[TBL] [Abstract][Full Text] [Related]
18. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemosensitivity of human lung cancer cell lines.
Ruckdeschel JC; Carney DN; Oie HK; Russell EK; Gazdar AF
Cancer Treat Rep; 1987; 71(7-8):697-704. PubMed ID: 3038314
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human interleukin-11 is unlikely to stimulate the growth of the most common solid tumors.
Soda H; Raymond E; Sharma S; Lawrence R; Cerna C; Gomez L; Schaub R; Von Hoff DD; Izbicka E
Anticancer Drugs; 1999 Jan; 10(1):97-101. PubMed ID: 10194552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
